Abstract
BACKGROUND: To evaluate the impact of treatment on health states that affect patients' quality of life in advanced follicular lymphoma.
METHODS: A quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TwiST) analysis was performed on data from a phase III clinical trial (Marcus et al, 2008).
RESULTS: Cyclophosphamide, vincristine, and prednisone plus rituximab (R-CVP)-treated patients gained a mean of 15.17 months in TWiST, 8.33 months in Q-TwiST, and 11.30 months less in disease relapse, without increase in toxicity compared with cyclophosphamide, vincristine, and prednisone (CVP)-treated patients.
CONCLUSION: Rituximab plus CVP-treated patients reached a significant and clinically meaningful improvement within 12 months in quality-adjusted survival compared with CVP. British Journal of Cancer (2010) 102, 19-22. doi:10.1038/sj.bjc.6605443 www.bjcancer.com Published online 17 November 2009 (C) 2010 Cancer Research UK
| Original language | English |
|---|---|
| Pages (from-to) | 19-22 |
| Number of pages | 4 |
| Journal | BJC: British Journal of Cancer |
| Volume | 102 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 5 Jan 2010 |
Keywords
- follicular lymphoma
- cyclophosphamide, vincristine, and prednisone
- rituximab
- quality-adjusted survival
- health-related quality of life
- quality-adjusted time without disease symptoms or toxicities of treatment
- OF-LIFE
- THERAPY
